Oldoni, EmanuelaSaunders, GaryBietrix, FlorenceGarcia Bermejo, Maria LauraNiehues, AnnaHoen, Peter A. C.Nordlund, JessicaHajduch, MarianScherer, AndreasKivinen, KatjaPitkänen, EsaMäkela, Tomi PekkaGut, Ivo GlynneScollen, SerenaKozera, ŁukaszEsteller, ManelShi, LemingUssi, AntonAndreu, Antonio L.Gool, Alian J. van2023-01-202023-01-202022Oldoni E, Saunders G, Bietrix F, Garcia Bermejo ML, Niehues A, 't Hoen PAC, Nordlund J, Hajduch M, Scherer A, Kivinen K, Pitkänen E, Mäkela TP, Gut I, Scollen S, Kozera Ł, Esteller M, Shi L, Ussi A, Andreu AL, van Gool AJ. Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report. Front Mol Biosci. 2022 Oct 13;9:974799. DOI: 10.3389/fmolb.2022.9747992296-889Xhttp://hdl.handle.net/10230/55349Personalised medicine (PM) presents a great opportunity to improve the future of individualised healthcare. Recent advances in -omics technologies have led to unprecedented efforts characterising the biology and molecular mechanisms that underlie the development and progression of a wide array of complex human diseases, supporting further development of PM. This article reflects the outcome of the 2021 EATRIS-Plus Multi-omics Stakeholder Group workshop organised to 1) outline a global overview of common promises and challenges that key European stakeholders are facing in the field of multi-omics research, 2) assess the potential of new technologies, such as artificial intelligence (AI), and 3) establish an initial dialogue between key initiatives in this space. Our focus is on the alignment of agendas of European initiatives in multi-omics research and the centrality of patients in designing solutions that have the potential to advance PM in long-term healthcare strategies.application/pdfeng© 2022 Oldoni, Saunders, Bietrix, Garcia Bermejo, Niehues, ’t Hoen, Nordlund, Hajduch, Scherer, Kivinen, Pitkänen, Mäkela, Gut, Scollen, Kozera, Esteller, Shi, Ussi, Andreu and van Gool. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.info:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fmolb.2022.974799EU initiativesBottlenecks in health dataMulti-omicsPersonalised medicineResearch infrastructuresTranslational medicineinfo:eu-repo/semantics/openAccess